According to CNBC TV18, Aarti Drugs has announced a significant leadership transition with Prakash M. Patil, Chairman, Managing Director and CEO, set to retire from the company effective September 30, 2026. Patil, who has been associated with the company since inception and served as Chairman since 2014, sought early retirement to facilitate an orderly leadership transition. The board has appointed Rashesh C. Gogri as Chairman of Aarti Drugs effective October 1, 2026. Gogri has been serving as the company's Managing Director since September 2014 and will continue in his existing role along with the new position. Additionally, the company approved the appointment of Adhish P. Patil as Managing Director for a five-year term effective October 1, 2026, subject to shareholder approval at the ensuing Annual General Meeting. Adhish P. Patil has been associated with the company as Chief Financial Officer since April 2014.
As reported by Business Standard, Aarti Drugs reported a consolidated net profit of ₹50.17 crore for the quarter ended June 2026, declining 6.94% from ₹53.91 crore in the corresponding quarter of the previous year. Despite the profit decline, the company demonstrated strong operational performance with revenue increasing 19.01% to ₹702.78 crore, compared with ₹590.51 crore in the same period last year. Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 36% to ₹89.79 crore from ₹65.83 crore a year earlier, with EBITDA margins improving to 13.97% in the quarter, compared with 12.55% in the year-ago period. Profit before depreciation and tax (PBDT) increased 40% to ₹71.33 crore from ₹51.11 crore, while profit before tax (PBT) grew 40% to ₹71.33 crore from ₹51.11 crore in the corresponding quarter of the previous year. The company's shares ended at ₹423.15, up by ₹2.56, or 10.55% on the BSE, reflecting positive market sentiment despite the mixed quarterly results.
According to CNBC TV18, the board approved several key appointments beyond the leadership transition. The company approved the appointment of Nilesh B. Patil as Whole-time Director for five years, subject to shareholder approval, replacing Uday M. Patil, who will retire by rotation and has not offered himself for re-appointment. The company said Uday M. Patil has been associated with Aarti Drugs for more than 25 years. Further, the board approved the re-appointment of Harshit M. Savla as Joint Managing Director and Harit P. Shah as Whole-time Director for a further five-year period effective June 1, 2027, subject to shareholder approval. Additionally, the board has approved the re-appointment of Hasmukh B. Dedhia, Ajit E. Venugopalan and Sandeep M. Joshi as Independent Directors for a second term of five years, effective March 29, 2027, subject to shareholder approval.
According to reports from Moneycontrol.com, Aarti Drugs Limited has officially notified stock exchanges about a Board Meeting scheduled for tomorrow, July 31, 2026. The company's Board of Directors will convene to consider and approve the consolidated financial results for the quarter and financial year ended March 31, 2026. This upcoming announcement is crucial for market participants seeking fresh insights into the pharmaceutical firm's operational and financial health, as reported by Moneycontrol.com.
As reported by CNBC TV18, the decisions made during the upcoming Board Meeting, particularly regarding the financial outcomes and leadership transition, are expected to provide clear guidance on the company's strategic direction and its capacity for future growth. Investors and analysts will be closely monitoring the announcements for any forward-looking statements or operational highlights that may influence trading sentiment. The leadership transition, combined with the company's strong operational performance and improved EBITDA margins, positions Aarti Drugs for continued growth despite the current quarter's profit decline. This procedural disclosure is a standard practice for publicly listed entities, offering transparency to shareholders and the broader investment community.
